Anti-NGF monoclonal antibody and use thereof
By preparing anti-NGF monoclonal antibodies with specific sequences, the NGF pathway is blocked, solving the safety and tolerability issues of existing anti-pain drugs and achieving effective treatment of NGF-mediated pain.
Patent Information
- Application Number
- PCT/CN2025/108346
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-07-12
- Filing Date
- 2025-07-14
- Publication Date
- 2026-01-15
AI Technical Summary
Existing pain medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics have safety and tolerability issues. NGF levels are elevated in trauma, inflammation, and chronic pain, leading to the maintenance and transmission of pain, and there is a lack of safe and effective treatment methods.
Develop an anti-NGF monoclonal antibody containing specific heavy and light chain complementarity-determining region sequences to block the NGF pathway and inhibit pain signaling. Specific implementation methods include preparing canine or feline-derived antibodies, producing them through nucleic acids, vectors, and host cells to form a pharmaceutical composition for treating related diseases.
It effectively inhibits NGF-mediated pain, especially autoimmune arthritis, bone cancer pain, and fracture pain, providing a safe and effective treatment approach.